XML 18 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Revenues $ 4,306,324 $ 2,909,282 $ 10,797,838 $ 8,413,667
Cost of goods sold 447,935 285,164 1,126,798 909,333
Gross profit 3,858,389 2,624,118 9,671,040 7,504,334
Operating expenses        
Selling, general and administrative expense 5,083,424 3,315,575 13,613,989 8,649,186
Depreciation and amortization 81,880 45,762 209,606 72,644
Bad debt expense 0 60,000 30,000 60,000
Total operating expenses 5,165,304 3,421,337 13,853,595 8,781,830
Operating loss (1,306,915) (797,219) (4,182,555) (1,277,496)
Other income / (expense)        
Other income 100,250 0 14,776 145
Interest expense (1,458) (46,014) (10,913) (80,925)
Total other income / (expense) 98,792 (46,014) 3,863 (80,780)
Net loss (1,208,123) (843,233) (4,178,692) (1,358,276)
Less: net loss attributable to noncontrolling interest (60,897) (6,257) (68,745) (7,311)
Net loss attributable to Sanara MedTech common shareholders $ (1,147,226) $ (836,976) $ (4,109,947) $ (1,350,965)
Basic loss per share of common stock $ (0.18) $ (0.35) $ (0.72) $ (0.78)
Diluted loss per share of common Stock $ (0.18) $ (0.35) $ (0.72) $ (0.78)
Weighted average number of common shares outstanding basic 6,230,648 2,366,181 5,730,554 1,724,848
Weighted average number of common shares outstanding diluted 6,230,648 2,366,181 5,730,554 1,724,848